Aortyx Company Research Report

Company Overview

• Name: Aortyx

• Mission of the Company: To provide life-saving solutions for patients with aortic diseases by delivering specialized tools designed to definitively heal the aorta to cardiovascular surgeons and aortic disease patients. Their goal is to reduce uncertainty, improve patient outcomes, and lower treatment costs in aortic disease care.

• Founded: 2018

• Founders: Researchers from the IQS School of Engineering and the Hospital Clínic de Barcelona

• Key People in the Company:

• Jordi Martorell (CEO and Co-Founder)

• Noemí Balà (CTO and Co-Founder)

• Salvador Borrós (CSO and Co-Founder)

• Vicenç Riambau (Medical Liaison and Co-Founder)

• Headquarters: No information is available

• Number of Employees: 17

• Revenue: No information is available

• Known for: Developing a new generation of endovascular devices to treat vascular diseases, focusing on tissue regeneration by mimicking the aorta biomechanical environment.

Products

Biomimetic Bioresorbable Adhesive Patch

• Description: A patented adhesive patch inserted in the aorta via an endovascular catheter and proprietary deployer. It adheres to the aorta covering tears, stops false lumen blood flow, and promotes natural repair and biointegration.

• Key Features:

• Bioresorbable: Designed to dissolve progressively after implantation, without toxic or inflammatory responses.

• Viscoelastic: Mimics mechanical properties of the aorta, expanding and contracting with cardiac cycles.

• Regenerative: Promotes re-endothelialization of the dissected part through a patented microstructure.

• Drug Delivery Platform: Can be used as a local drug delivery platform due to its drug-loading potential.

Recent Developments

• New Partnerships: Aortyx has a collaboration with CIMNE.

• Recognition: Selected as one of the 10 Catalonia Exponential Leaders 2023, celebrating its outstanding contributions.

• Anniversary: Celebrated its 5th anniversary, marking a significant milestone in transforming aortic healthcare.

Financial Overview

• Funding:

• Private Equity: €4.1 million

• Public Grants: €4.2 million

• Public Loans: €1.3 million

• Patents: Holds 3 patent families

• Awards and Recognitions:

• 2020 Alex Casta Award

• 2020 EIT Health Catapult Finalist

• Imagine IF! Innovation Forum Finalist

Technology and Research

• Aortyx focuses on advanced technology development for treating aortic dissection.

• Emphasis on creating a suitable environment for cell migration and proliferation to mimic natural dynamics of the aorta.

Notable Achievements

• Successful deployment and validation of the biomimetic bioresorbable adhesive patch for aortic dissection.

• The patch has seen extensive development, including the design of the deployer and the system for catheter delivery.

This structured report presents a detailed overview of Aortyx, summarizing key aspects, product information, and recent achievements with a focus on their pioneering solutions for vascular diseases.